Glypican 3 has a higher sensitivity than alpha‐fetoprotein for testicular and ovarian yolk sac tumour: immunohistochemical investigation with analysis of histological growth patterns
Authors:
- 28 April 2010
- journal article
- Published by Wiley in Histopathology
- Vol. 56 (6) , 750-757
Abstract
Zynger D L, McCallum J C, Luan C, Chou P M & Yang X J (2010) Histopathology 56, 750–757 Glypican 3 has a higher sensitivity than alpha‐fetoprotein for testicular and ovarian yolk sac tumour: immunohistochemical investigation with analysis of histological growth patternsAims: Glypican 3 (GPC3) has been reported to be overexpressed in yolk sac tumour (YST), but the sensitivity has not been compared with α‐fetoprotein (AFP). YST can form numerous growth patterns and the expression of GPC3 in these patterns has not been studied. The aim was to address these aspects.Methods and results: Sections from testicular or ovarian YST were subjected to immunohistochemistry using GPC3 (n = 39) and AFP (n = 24). Overall immunoreactivity for each case and specific histological patterns were semiquantitatively evaluated (0–3+) and intensity of reactivity was scored (0–3). All cases expressed GPC3 (1+, 5%; 2+, 8%; 3+, 87%) with strong intensity (2.9). The majority expressed AFP (58%) but immunoreactivity was often focal (0, 42%; 1+, 33%; 2+, 25%) and intensity was low (1.0). Using GPC3, >75% of the microcystic (n = 38), macrocystic (n = 26), solid (n = 21), glandular‐alveolar (n = 8), endodermal sinus (n = 7), polyvesicular vitelline (n = 5), enteric (n = 4) and micropapillary (n = 2) growth patterns displayed 2+ or 3+ positivity.Conclusions: YST can display a variety of growth patterns that can be confused with other germ cell tumour components. GPC3 detects all growth patterns tested and has a higher sensitivity for detecting YST than AFP.Keywords
This publication has 42 references indexed in Scilit:
- Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cellsBiochemical and Biophysical Research Communications, 2009
- Anti–Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver CancerCancer Research, 2008
- Extragonadal Germ Cell Tumors: A Review With Emphasis on Pathologic Features, Clinical Prognostic Variables, and Differential Diagnostic ConsiderationsAdvances in Anatomic Pathology, 2007
- The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinomaLaboratory Investigation, 2005
- Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issuesLaboratory Investigation, 2005
- Gene Expression Profiling of Early- and Late-Relapse Nonseminomatous Germ Cell Tumor and Primitive Neuroectodermal Tumor of the TestisClinical Cancer Research, 2004
- Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signalingExperimental & Molecular Medicine, 2003
- Elucidation of the Structural Features of Heparan Sulfate Important for Interaction with the Hep-2 Domain of FibronectinJournal of Biological Chemistry, 2000
- Functions of Cell Surface Heparan Sulfate ProteoglycansAnnual Review of Biochemistry, 1999
- Immunohistochemical expression of monoclonal antibody 43‐9F in testicular germ cell tumoursInternational Journal of Andrology, 1998